之江生物(688317.SH):丙型肝炎病毒(HCV)核酸測定試劑盒獲得國家三類醫療器械註冊證
格隆匯3月26日丨之江生物(688317.SH)公佈,近期1項產品獲得國家三類醫療器械註冊證,產品名稱:丙型肝炎病毒(HCV)核酸測定試劑盒(熒光PCR法)。公司最新獲得認證的產品,採用高敏丙肝核酸檢測方案(靈敏度15IU/mL),較常規試劑靈敏度大幅提升,檢測窗口期大大縮短,準確把控HCV感染者的診療黃金時間,可在肝病嚴重度評估、治療期間檢測、治療終點判斷等階段動態監測HCV病毒載量,鞏固了公司在肝炎病毒系列檢測試劑產品的領先優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.